Compare PLBC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBC | NGNE |
|---|---|---|
| Founded | 1980 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.9M | 327.8M |
| IPO Year | 2002 | 2014 |
| Metric | PLBC | NGNE |
|---|---|---|
| Price | $55.83 | $31.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $57.67 | ★ $63.57 |
| AVG Volume (30 Days) | 64.8K | ★ 127.6K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 1.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $39.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.70 | $14.65 |
| 52 Week High | $57.51 | $37.27 |
| Indicator | PLBC | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 65.03 |
| Support Level | $50.35 | $19.27 |
| Resistance Level | N/A | $33.00 |
| Average True Range (ATR) | 1.41 | 2.05 |
| MACD | 0.03 | 0.34 |
| Stochastic Oscillator | 59.09 | 91.04 |
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.